2.
Baseline characteristics after propensity score-matched stratification by regimens
| Characteristics | PPCT (n=105) [n (%)] | Bev+PPCT (n=105) [n (%)] | P |
| ECOG PS, Eastern Cooperative Oncology Group Performance Score; EGFR, epidermal growth factor receptor; PPCT, platinum-pemetrexed-based chemotherapy; Bev, bevacizumab. | |||
Age (
) (year)
|
55.8±10.4 | 56.2±10.2 | 0.989 |
| ≥60 years | 39 (37.1) | 43 (41.0) | 0.336 |
| Male | 53 (50.5) | 48 (45.7) | 0.290 |
| ECOG PS | 0.169 | ||
| 0−1 | 94 (89.5) | 101 (96.2) | |
| ≥2 | 11 (10.5) | 4 (3.8) | |
| Smoking status | 0.667 | ||
| No | 71 (67.6) | 72 (68.6) | |
| Yes | 34 (32.4) | 33 (31.4) | |
| Comorbidities | 0.060 | ||
| Hypertension | 23 (21.9) | 16 (15.2) | |
| Diabetes | 8 (7.6) | 3 (2.9) | |
| Cardiovascular disease | 6 (5.7) | 3 (2.9) | |
| Thrombosis disease | 0 (0) | 1 (1.0) | |
| Cerebrovascular disease | 1 (1.0) | 3 (2.9) | |
| Other | 13 (12.4) | 28 (26.7) | |
| Baseline histology | 0.998 | ||
| Adenocarcinoma | 102 (97.1) | 102 (97.1) | |
| Large cell carcinoma | 1(1.0) | 1 (1.0) | |
| Bronchoalveolar carcinoma | 1 (1.0) | 1 (1.0) | |
| Mixed | 1 (1.0) | 1 (1.0) | |
| Sensitizing driven mutation | |||
| EGFR positive | 25 (23.8) | 28 (26.7) | 0.512 |
| T790M positive | 3 (2.9) | 2 (1.9) | 0.500 |
| ALK positive | 9 (8.6) | 8 (7.6) | 0.500 |
| C-MET positive | 2 (1.9) | 1 (1.0) | 0.500 |
| ROS-1 positive | 0 (0) | 0 (0) | − |
| Pemetrexed regimens | 105 (100) | 105 (100) | − |
| Brain metastases | 14 (13.3) | 13 (12.4) | 0.500 |
| Pleural invasion | 43 (41.0) | 42 (40.0) | 0.500 |
| Weight loss >5% | 8 (7.6) | 5 (4.8) | 0.284 |
| History of hemoptysis | 8 (7.6) | 7 (6.7) | 0.500 |
| Maintenance therapy | 46 (43.8) | 67 (63.8) | 0.001 |
| Previous surgery | 17 (16.2) | 21(20.0) | 0.296 |
| Radiotherapy history | 18 (17.1) | 22 (21.0) | 0.299 |